BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29395168)

  • 1. Comparing Topical Treatments for Basal Cell Carcinoma.
    Shaw FM; Weinstock MA
    J Invest Dermatol; 2018 Mar; 138(3):484-486. PubMed ID: 29395168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
    Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
    Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
    Lecluse LL; Spuls PI
    Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
    Jansen MHE; Mosterd K; Arits AHMM; Roozeboom MH; Sommer A; Essers BAB; van Pelt HPA; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
    J Invest Dermatol; 2018 Mar; 138(3):527-533. PubMed ID: 29045820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'.
    Nijsten T
    Br J Dermatol; 2015 Jan; 172(1):12. PubMed ID: 25581586
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.
    Arits A; Nelemans P; Kelleners-Smeets N
    Br J Dermatol; 2015 Jan; 172(1):11-2. PubMed ID: 25581585
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
    Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
    J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
    Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
    J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
    Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
    Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facial extensive recurrent basal cell carcinoma: successful treatment with photodynamic therapy and imiquimod 5% cream.
    Requena C; Messeguer F; Llombart B; Serra-Guillén C; Guillén C
    Int J Dermatol; 2012 Apr; 51(4):451-4. PubMed ID: 22435437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
    Rhodes LE; de Rie MA; Leifsdottir R; Yu RC; Bachmann I; Goulden V; Wong GA; Richard MA; Anstey A; Wolf P
    Arch Dermatol; 2007 Sep; 143(9):1131-6. PubMed ID: 17875873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
    Aguilar M; de Troya M; Martin L; Benítez N; González M
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy for basal cell carcinoma.
    Fargnoli MC; Peris K
    Future Oncol; 2015 Nov; 11(22):2991-6. PubMed ID: 26550910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
    Devirgiliis V; Panasiti V; Curzio M; Gobbi S; Rossi M; Roberti V; Calvieri S
    Dermatol Online J; 2008 Feb; 14(2):25. PubMed ID: 18700128
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of pigmentation on photodynamic therapy.
    Apalla Z; Lallas A; Sotiriou E; Ioannides D
    Lancet Oncol; 2013 Aug; 14(9):e339-40. PubMed ID: 23896270
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes.
    Sebaratnam DF; Venugopal SS; Murrell DF
    J Eur Acad Dermatol Venereol; 2011 Jan; 25(1):117-8. PubMed ID: 20456551
    [No Abstract]   [Full Text] [Related]  

  • 18. Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study.
    van Delft LCJ; Nelemans PJ; Jansen MHE; Arits AHMM; Roozeboom MH; Hamid MA; Mosterd K; Kelleners-Smeets NWJ
    J Am Acad Dermatol; 2019 Apr; 80(4):1022-1028. PubMed ID: 30582993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
    Itkin A; Gilchrest BA
    Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pigmentation on photodynamic therapy - Authors' reply.
    Arits A; Kelleners-Smeets NW
    Lancet Oncol; 2013 Aug; 14(9):e340. PubMed ID: 23896273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.